AN2 Therapeutics, Inc. (ANTX)
Nasdaq: ANTX · Pharmaceutical Preparations · Menlo Park, CA · filing with the SEC since 2021
Who owns AN2 Therapeutics, Inc.
As filed with the SECHolders of 5% or more
6
Commodore Capital LP holds 9.9% of Common Stock, par value $0.00001 per share, as its SCHEDULE 13G filed Mar 16, 2026 says.
Directors and officers
15
report now, of 18 people on the record since 2022. Their holdings as a group are not read here.
Institutions as a whole
n/a
The record does not read the share held by managers that file Form 13F, so none is printed and no split of the rest is estimated. What it holds is the 6 named at left.
Holders of 5% or moreshare of the class, as filed
Commodore Capital LP
SCHEDULE 13G · filed Mar 16, 2026 · Common Stock, par value $0.00001 per share
Coastlands Capital LP
SCHEDULE 13G · filed Jun 4, 2025 · Common Stock
Vivo Opportunity Fund Holdings, L.P.
SCHEDULE 13G · filed Mar 13, 2026 · Common Stock, par value $0.00001 per share
Eric Easom
SCHEDULE 13G/A · filed Feb 13, 2026 · Common Stock, par value $0.00001 per share · 6.2% in Feb 13, 2025
Adjuvant Capital GP, L.P.
SCHEDULE 13G/A · filed Feb 28, 2025 · Common Stock, $0.00001 par value per share
Millennium Management LLC
SCHEDULE 13G · filed Mar 13, 2026 · Common Stock, par value $0.00001 per share
Almitas Capital LLC
SCHEDULE 13G/A · filed May 15, 2026 · Common Stock · reported falling below 5%, from 5.4% in Feb 17, 2026
Brii Biosciences Limited
SCHEDULE 13G/A · filed Feb 14, 2025 · Common Stock, $0.00001 par value per share · reported falling below 5%
BML Investment Partners, L.P.
SCHEDULE 13D/A · filed Jun 18, 2025 · Common Stock, par value $0.00001 per share · reported falling below 5%, from 10.7% in May 30, 2025
RA Capital Management, L.P.
SCHEDULE 13G/A · filed Feb 14, 2025 · Common Stock, $0.00001 par value per share · reported falling below 5%
Frazier Life Sciences Public Fund, L.P.
SCHEDULE 13G/A · filed Feb 14, 2025 · Common Stock · reported falling below 5%
TCG Crossover GP I, LLC
SCHEDULE 13G/A · filed Feb 14, 2025 · Common Stock, $0.00001 par value · reported falling below 5%
What ANTX reports owning in othersstakes of 5% or more, and other ties
AN2 Therapeutics, Inc. reports no stake in another company in the record.
Insider tradesForm 4
21sales
1purchases
8sales on a scheduled plan
6people selling
$400,000sold, in dollars
$0bought, in dollars
Open-market trades on Form 4 from Nov 6, 2025 to Nov 6, 2026. A scheduled plan is a selling program set in advance under SEC rule 10b5-1. The trades are listed as filed and do not feed the grade.
By calendar yearSoldBought
2026 runs to Nov 6, 2026. Dollars as filed, summed by the transaction date.
People who traded in the window7 of 28 on the roster
| Person | Role as filed | Sales | Sold | On a plan | Buys | Bought |
|---|---|---|---|---|---|---|
| Readnour Robin Shane | director | 8 | $300,000 | 8 | 0 | $0 |
| Eizen Joshua M | See Remarks | 4 | $100,000 | 0 | 0 | $0 |
| Fitzpatrick Margaret M | director | 0 | $0 | 0 | 1 | $0 |
| Day Lucy | Chief Financial Officer | 2 | $0 | 0 | 0 | $0 |
| Chanda Sanjay | Chief Development Officer | 2 | $0 | 0 | 0 | $0 |
| Prior Stephen David | Chief Strategy Officer | 2 | $0 | 0 | 0 | $0 |
| Williams Sarah Joanne | Principal Accounting Officer | 3 | $0 | 0 | 0 | $0 |